DAPASAN TRIO 10

About

DAPASAN TRIO typically refers to a triple combination therapy for the management of type 2 diabetes mellitus, often comprising Dapagliflozin (an SGLT2 inhibitor), Metformin (a biguanide), and a third agent, commonly a Dipeptidyl Peptidase-4 (DPP-4) inhibitor such as Sitagliptin. This comprehensive approach targets multiple pathophysiological pathways involved in glucose dysregulation. Dapagliflozin enhances urinary glucose excretion, Metformin reduces hepatic glucose production and improves insulin sensitivity, while a DPP-4 inhibitor increases incretin levels, leading to glucose-dependent insulin release and reduced glucagon secretion. This multi-faceted mechanism provides robust glycemic control, effectively lowering HbA1c levels. Furthermore, this combination may offer additional benefits including potential weight management, and the established cardiovascular and renal protective effects associated with dapagliflozin, making it a powerful option for patients requiring intensive blood sugar management.

Uses

• Comprehensive glycemic control in type 2 diabetes mellitus.
• Adjunct to diet and exercise when dual therapy is insufficient.
• Reduction of HbA1c levels through multiple mechanisms.
• Management of blood sugar in patients requiring intensive therapy.

Directions For Use

Take orally, usually once or twice daily with meals, as prescribed by your healthcare provider.

Benefits

• Potent and comprehensive blood glucose reduction.
• Targets multiple pathophysiological defects in T2DM.
• May lead to modest weight loss.
• Offers cardiovascular and renal protective effects.
• Improves insulin secretion and sensitivity.
• Reduces risk of diabetes-related complications.

Side Effects

• Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)
• Genital mycotic infections
• Urinary tract infections
• Hypoglycemia (especially with other diabetes meds)
• Lactic acidosis (rare, but serious with metformin)
• Pancreatitis (rare, with DPP-4 inhibitors)
• Joint pain (with DPP-4 inhibitors)
• Headache
• Dizziness
• Increased urination
• Rash
• Vitamin B12 deficiency (with metformin)

Safety Measures

• Alcohol - Avoid excessive alcohol intake due to increased risk of lactic acidosis (metformin) and hypoglycemia.
• Pregnancy - Not recommended during pregnancy; insulin is generally preferred for glycemic control in pregnant women.
• Breastfeeding - Not recommended during breastfeeding as components may pass into breast milk and affect the infant.
• Liver - Metformin is contraindicated in severe hepatic impairment; dapagliflozin and DPP-4 inhibitors require caution or dose adjustment in liver conditions.
• Kidney - Metformin is contraindicated in severe renal impairment; dapagliflozin and DPP-4 inhibitors require dose adjustment or are not recommended below certain eGFR thresholds.
• Lung - Use with caution in conditions causing hypoxia, as this may increase the risk of lactic acidosis with metformin.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.